Skip to main content
x

Recent articles

ASCO 2025 preview – Merus tops Bicara

Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.

Uncontrolled trial strategy sinks UroGen

The company's refusal to run a randomised pivotal study of UGN-102 leads to an adcom thumbs down.

Relay pulls ahead of Lilly

A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.

J&J gets a smouldering endorsement

An FDA adcom votes in favour of expansion into a multiple myeloma precursor.

Asia stymies Columvi's expansion

Starglo isn't applicable to a US population, an adcom rules.

Pfizer bets big on a bispecific

The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.